279 completed, 26 recruiting, 26 terminated, 24 unknown. 391 Phase 1, 92 Phase 2.
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder Psilocybin - Treatment Resistant Depression, Substance Use Disorders | Phase 1 / Phase 2 | Not yet recruiting | Indiana University | 50 | 2027-02-01 | 2026-10-23 |
| A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients PDC-1421 Capsule - Major Depressive Disorder | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 12 | 2027-01-15 | 2026-04-20 |
| MLS101 Study in PMDD MLS101 psilocybin, Placebo capsules - Premenstrual Dysphoric Disorder ( PMDD), PMDD | Phase 1 | Not yet recruiting | MycoMedica Life Sciences PBC | 32 | 2026-12-01 | 2026-09-14 |
| Shortened LSD Intervention for Major Depressive Disorder LSD, Risperidone - Major Depression Moderate, Major Depression Severe | Phase 1 | Not yet recruiting | Johns Hopkins University | 10 | 2026-10-01 | 2026-09-22 |
| Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder Sham iTBS, TMS, D-cycloserine - Major Depression, Healthy Participants | Phase 1 / Phase 2 | Recruiting | Mclean Hospital | 100 | 2026-10-01 | 2026-10-30 |
| Pregnenolone for Cannabis Use Disorder and Depression Pregnenolone - Cannabis Use Disorder, Major Depressive Disorder (MDD) | Phase 1 / Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 20 | 2026-09-01 | 2026-07-06 |
| A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects Selegiline Transdermal Delivery System - Major Depressive Disorder (MDD) | Phase 1 | Active not recruiting | Corium Innovations, Inc. | 232 | 2026-08-23 | 2026-08-31 |
| A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder ABBV-932, Itraconazole - Bipolar Disorder | Phase 1 | Recruiting | AbbVie | 20 | 2026-08-20 | 2026-09-16 |
| Cannabidiol Oil for Treatment-Resistant Major Depression Full-spectrum CBD oil 100 mg/mL, Placebo oil (MCT oil) - Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD) | Phase 1 / Phase 2 | Recruiting | Universidade do Sul de Santa Catarina | 120 | 2026-06-01 | 2026-07-10 |
| Pattern Separation in Major Depressive Disorder SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo - Major Depressive Disorder (MDD) | Phase 1 | Recruiting | Jeffrey Miller | 30 | 2026-06-01 | 2026-09-15 |
| First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection SP-101 injection, Placebo - Major Depressive Disorder, Healthy Volunteer | Phase 1 | Not yet recruiting | Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. | 80 | 2025-12-23 | 2026-01-12 |
| Ketamine Biomarker Validation Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg) - Treatment Resistant Depression (TRD) | Phase 1 | Withdrawn | Soterix Medical | 2025-12-20 | 2026-10-19 | |
| Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) Ketamine, Cognitive Behavioural Therapy - Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD) | Phase 1 / Phase 2 | Not yet recruiting | South West Sydney Local Health District | 20 | 2025-12-10 | 2025-11-25 |
| First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) ALN-SNCA, Placebo - Parkinsons Disease | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 46 | 2025-12-05 | 2026-09-21 |
| To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects LY03021, placebo - Major Depressive Disorder | Phase 1 | Enrolling by invitation | Luye Pharma Group Ltd. | 98 | 2025-10-28 | 2026-01-27 |
| Adaptation and Validation of the Hypomanic Personality Scale (HPS-6) to Romanian Hypomanic Personality Scale - 6 - Bipolar Disorder (BD) | Phase 1 / Phase 2 | Recruiting | Babes-Bolyai University | 50 | 2025-09-22 | 2026-02-10 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day - Schizophrenia, Bipolar I Disorder | Phase 1 / Phase 2 | Recruiting | Mapi Pharma Ltd. | 24 | 2025-08-01 | 2026-05-01 |
| Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for Refractory Anorexia Nervosa With Comorbid Obsessive Compulsive Disorder or Major Depressive Disorder ExAblate Neuro 4000 - Anorexia Nervosa (DSM-IV Revised Criteria) | Phase 1 | Recruiting | Sunnybrook Health Sciences Centre | 10 | 2025-08-01 | 2025-08-14 |
| The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression., Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD, Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. - Anxiety, Depression | Phase 1 | Completed | Rakitzi, Stavroula | 107 | 2025-06-02 | 2026-08-04 |
| Theta-Burst Stimulation to Treat Depression Spaced iTBS, Compressed iTBS - Major Depressive Disorder (MDD) | Phase 1 | Recruiting | Centre for Addiction and Mental Health | 84 | 2025-06-01 | 2025-06-24 |
Showing 20 of 391. Sign in to see all of them.
Depressive Disorder, Major (211) · Depression (92) · Bipolar Disorder (75) · Depressive Disorder (67) · Schizophrenia (39) · Depressive Disorder, Treatment-Resistant (34) · Anxiety Disorders (25) · Stress Disorders, Post-Traumatic (16) · Psychotic Disorders (14) · Mental Disorders (11) · Depression, Postpartum (10) · Substance-Related Disorders (10) · Alcoholism (6) · Dysthymic Disorder (6)
Mental Disorders (380) · Depressive Disorder (225) · Behavior (98) · Behavioral Symptoms (91) · Bipolar and Related Disorders (75) · Schizophrenia Spectrum and Other Psychotic Disorders (39) · Pathological Conditions, Signs and Symptoms (19) · Nervous System Diseases (18) · Trauma and Stressor Related Disorders (18) · Chemically-Induced Disorders (17) · Stress Disorders, Traumatic (14) · Neurologic Manifestations (13) · Signs and Symptoms (13) · Female Urogenital Diseases and Pregnancy Complications (12)
Ketamine (26) · alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol (16) · Paliperidone Palmitate (14) · Escitalopram (9) · Therapeutics (8) · Cognitive Behavioral Therapy (7) · Desvenlafaxine Succinate (6) · Psilocybin (6) · Sertraline (6) · Transcranial Magnetic Stimulation (6) · Bupropion (5) · Citalopram (5) · N-Methyl-3,4-methylenedioxyamphetamine (5) · seltorexant (5) · Duloxetine Hydrochloride (4)
GlaxoSmithKline (31) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (24) · Eli Lilly and Company (19) · Luye Pharma Group Ltd. (10) · National Institute of Mental Health (NIMH) (10) · Mclean Hospital (8) · Janssen Research & Development, LLC (7) · New York State Psychiatric Institute (6) · University of California, Los Angeles (6) · Washington University School of Medicine (6) · Yale University (6) · Otsuka Pharmaceutical Development & Commercialization, Inc. (5) · Pfizer (5) · University Hospital, Basel, Switzerland (5) · AbbVie (4)
United States (194) · United Kingdom (30) · Canada (23) · China (21) · Germany (17) · Australia (11) · Netherlands (10) · Brazil (7) · Belgium (6) · Israel (5) · Switzerland (5) · Egypt (4) · India (4) · Japan (4) · Singapore (3)
Matthias E Liechti, MD (5) · Carlos A Zarate, M.D. (3) · Amy Sun, MD, PhD, MBA (2) · Catherine Harmer (2) · Charles R Conway, MD (2)
PMID 22700038, PMID 29912955, PMID 25150403, PMID 31784354, PMID 32241310, PMID 35963959, PMID 40484114, PMID 14702256, PMID 15780843, PMID 16319710, PMID 16585452, PMID 16894061, PMID 17429407, PMID 18061147, PMID 18227146, PMID 18762591, PMID 18996507, PMID 19454920, PMID 19545857, PMID 19736358, PMID 19744406, PMID 19897179, PMID 19914605, PMID 19995444, PMID 20673547, PMID 20679587, PMID 20854181, PMID 21450159, PMID 21459988, PMID 21715530, PMID 21731830, PMID 21736514, PMID 22065593, PMID 22125120, PMID 22296967, PMID 22297150, PMID 22409700, PMID 22473055, PMID 22521148, PMID 22570264, PMID 22574166, PMID 22722512, PMID 22945620, PMID 23300127, PMID 23482332, PMID 23562618, PMID 23685546, PMID 23773978, PMID 23800483, PMID 23805231
2016 (3), 2015 (2), 2017 (2), R01MH134538 (2), 1UG3DA066242-01 (1), 2014 (1), 2018 (1), 2019 (1), 2025 (1), K01DA029645 (1), K01MH112876 (1), K23MH064528 (1), K23MH074860 (1), K24DA000435 (1), K24MH102743 (1)